Speakers & agenda
(subject to change)
08.30: Registration welcome coffee, networking, exhibition
09.20: Welcome and housekeeping
Session 1: Chair Professor Andrew Miller
09.30: Dr Mark Edbrooke, Oncology iMED, AstraZeneca, Cambridge, UK
Therapeutic antisense oligonucleotides – significant progress towards a viable drug platform for tackling intractable targets in oncology
10.00: Professor Tom Brown, University of Oxford, UK
Chemical ligation of DNA, biocompatibility and applications of artificial chemical linkages
10.30: Dr Marcel Hollenstein, Pasteur Institute, Paris, France
Modified nucleoside triphosphates: synthetic tools for the development of catalytic DNAs
11.00: Refreshment break
11.30: Professor Francesco Muntoni, University College London, London, UK
Chronic low-dose morpholino antisense oligomer to generate SMA mice with intermediate phenotype
12.00: Professor Peter Zammit, King’s College London, London, UK
Ameliorating pathogenesis by removing an exon containing a missense mutation: a potential exon-skipping therapy for laminopathies
12.30: Dr Igor Vorechovsky, University of Southampton, Southampton, UK
Antisense oligonucleotides targeting intronic sequences: NMD switch exons in focus
1300: Lunch
Session 2: Chair Professor Tom Brown
13.50: Dr David Blakey, CSO, MiNA therapeutics, London, UK
Small activating RNA therapeutics for transcriptional gene activation
14.20: Dr Viorel Simion, CNRS, Université d’Orléans and Inserm, France
LentiRILES : a novel cell-based bioluminescence platform for screening of miRNA formulations for miRNA-based cancer therapy
14.50: Dr Sylvain Ladame, Imperial College London, London, UK
Engineered Peptide Nucleic Acids (PNAs) and Cancer: therapeutic and diagnostic applications
15.20: Refreshment break
15.50: Dr Philipp Holliger, MRC Laboratory of Molecular Biology, Cambridge, UK
Synthetic genetics
16.20: Professor Andrew Miller, King’s College London, London, UK
The opportunities for medicine presented by the chemistry and biology of dinucleoside polyphosphates
16.50: Dr Simon Richardson, Biopharmaceutical Sciences, University of Greenwich, UK
Attenuated Anthrax Toxin: application to cytosolic antisense and siRNA delivery
17.20: DISCUSSION AND CLOSE
